Consolidated Statement of Cash Flows

For the year ended 31 December 2024

	Notes	31 December 2024 <u></u> 4'000	31 December 2023 <u></u> 半'000
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit for the year		2,313,667	2,051,529
Adjustments for non-cash items:			
Depreciation of Property, Plant and Equipment	7	1,688,316	1,711,751
Amortisation of Long-term Prepayments	8	27,262	27,262
Depreciation of Right-of-Use Assets	9	117,990	110,900
Amortisation of Intangible Assets	10	39,970	37,395
Depreciation of Biological Assets	11	566,338	574,264
Loss arising from Changes in Fair Value less Cost to Sell of Crops		12,218	9,978
Provision for Employee Retirement Benefits	23	182,398	142,712
Provision for Inventories and Trade Receivables	13,14	185,866	86,382
Share Based Payment Expense		37,163	30,820
Finance Cost, net	31	530,260	527,019
Other Expenses, net	30	63,166	64,461
Share of Results of Associate	12	1,774	1,064
Zakat	25	105,326	85,101
Income Tax	24,25	44,334	29,175
		5,916,048	5,489,813
Changes in Working Capital:			
Inventories		348,415	(1,063,947)
Biological Assets		(11,161)	(7,885)
Trade Receivables, Prepayments and Other Receivables		11,740	(458,951)
Trade and Other Payables		(143,111)	591,073
Cash From / (Used in) Working Capital		205,883	(939,710)
Employee Retirement Benefits Paid	23	(70,501)	(59,222)
Zakat and Income Tax Paid	24,25	(22,948)	(8,255)
Net Cash From Operating Activities		6,028,482	4,482,626
CASH FLOWS FROM INVESTING ACTIVITIES			, ,
Redemption / (Investment) in Time Deposit		1,876,250	(1,876,250)
Additions in Long-term Prepayments	8	(27,500)	-
Proceeds from Sale of Equity Investment	12	-	19,781
Purchase of Warehouse Facilities	1	(187,870)	
Additions to Property, Plant and Equipment		(3,573,721)	(2,505,890)
Proceeds from the Disposal of Property, Plant and Equipment		137,383	73,741
Additions to Intangible Assets	10	(60,504)	(24,517)
Additions to Biological Assets		(1,072,814)	(1,095,263)
Proceeds from the Disposal of Biological Assets		287,126	228,358
Net Cash Used in Investing Activities		(2,621,650)	(5,180,040)
CASH FLOWS FROM FINANCING ACTIVITIES		(=,0=7,0007	(5,100,010)
Proceeds from Loans and Borrowings		14,767,862	16,099,196
Repayment of Loans and Borrowings		(16,576,340)	(13,634,845)
Purchase of Additional Stake in a Subsidiary	1	(10,570,540)	(255,000)
Finance Cost Paid	'	(645,039)	(559,199)
Dividend Paid	40	(986,875)	(980,576)
Settlement of Treasury Shares	70	64,010	273,316
Principal Element of Lease Payments		(122,093)	(100,764)
Interest Element of Lease Payments		(5,720)	(15,208)
Directors' Remuneration		(5,477)	(4,994)
Transactions with Non-Controlling Interests		(29,651)	(781)
Net Cash (Used in) / From Financing Activities		(3,539,323)	821,145
Net Clash (Used In) / From Financing Activities Net Change in Cash and Cash Equivalents		(3,539,323)	123,731
Cash and Cash Equivalents Cash and Cash Equivalents			
		666,336	546,916
Effect of Movements in Exchange Rates on Cash and Cash Equivalents		(5,631)	(4,311)

The accompanying notes form an integral part of these Consolidated Financial Statements, which have been authorised for issue by the Board of Directors on behalf of the Shareholders and signed on its behalf by: